Researchers are aggressively studying the emergence of the omicron variant. One of the many questions they're hoping to answer is how well current COVID-19 treatments and therapies will work against omicron. "If you look at the structure ofomicronand compare it to the structure of previous stra...
China is defending its zero-COVID-19 approach as more countries open borders and loosen restrictions. Zhong Nanshan, China's top epidemiologist, shares more insights with us. He says that the policy is necessary.RELATED STORIES LSE Prof. Jin Keyu on China's economic policy, ...
However, there is still no specific drugs to treat COVID-19. Traditional Chinese medicine (TCM) was used in the treatment of COVID-19 during the early stages of the outbreak in China. Some ancient TCM prescriptions, which were efficacious in the treatment of severe acute respiratory syndrome ...
This paper aimed to review and analyse the published studies about COVID‐19 diagnosis, prevention, and treatment.doi:10.1111/ijcp.13886Haitham SaeedClinical Pharmacy Department Faculty of Pharmacy Beni‐Suef University Beni‐Suef EgyptHasnaa Osama...
Novel Coronavirus Disease 2019 (COVID-19)Pandemic: Research Progress of CurrentMedical Therapy Novel CoronavirusClinical TrialDrug TherapyPotential Drug DevelopmentThe novel coronavirus outbreak in Wuhan, Hubei Province, China in late December 2019 which poses a serious threat to thewhole world. At ...
Remdesivir for COVID‐19: evidence review of the clinical benefit and harmInstitutNationaldelaSanteEtdelaRecherche Medicale,France Informationprovidedby(... M Blockman,K Cohen,R Waal,... 被引量: 0发表: 2020年 Evidence that remdesivir treatment reduces viral titers in patients with COVID-19 Remdes...
The overall COVID-19 infections in China have entered a low prevalence level since mid-May, and the vast majority of COVID-19 patients show mild symptoms, medical experts said. Despite a recent increase, the total amount of fever clinic patients is far less than that during the peak of th...
SARS-CoV-2 COVID-19 Vaccination Antibody titer Cellular immunity Adaptive immunity SARS-CoV-2 variants 1. Introduction The pandemic of COVID-19 presents significant problems that are managed only in part by the nations. SARS-CoV-2 pathogenicity is a combination of severe and high infectivity. ...
We have grouped these trials into four categories: prophylaxis; treatment of outpatients with mild COVID ; treatment of hospitalised patients with moderate COVID ; and treatment of hospitalised patients with moderate or severe disease. The most common therapeutic agent being trialled currently is ...
COVID-19 and impact on peer review As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us kno...